vs
Side-by-side financial comparison of Creative Media & Community Trust Corp (CMCT) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
Creative Media & Community Trust Corp is the larger business by last-quarter revenue ($28.5M vs $18.7M, roughly 1.5× CytomX Therapeutics, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -125.8%, a 124.9% gap on every dollar of revenue. On growth, Creative Media & Community Trust Corp posted the faster year-over-year revenue change (3.6% vs -25.7%). Over the past eight quarters, Creative Media & Community Trust Corp's revenue compounded faster (-8.5% CAGR vs -15.9%).
Creative Media & Community Trust Corp is a U.S.-headquartered real estate investment trust operating two core segments: it owns, manages and develops creative media facilities including professional film and TV production studios, plus community-focused assets such as affordable housing, neighborhood healthcare centers and local commercial spaces, serving media operators and local communities nationwide.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CMCT vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.5M | $18.7M |
| Net Profit | $-11.4M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | -125.6% | -6.9% |
| Net Margin | -125.8% | -0.8% |
| Revenue YoY | 3.6% | -25.7% |
| Net Profit YoY | -11.4% | 97.6% |
| EPS (diluted) | $-3.89 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.5M | — | ||
| Q3 25 | $26.2M | — | ||
| Q2 25 | $29.7M | $18.7M | ||
| Q1 25 | $32.3M | $50.9M | ||
| Q4 24 | $27.5M | $38.1M | ||
| Q3 24 | $28.6M | $33.4M | ||
| Q2 24 | $34.4M | $25.1M | ||
| Q1 24 | $34.0M | $41.5M |
| Q4 25 | $-11.4M | — | ||
| Q3 25 | $-12.5M | — | ||
| Q2 25 | $-9.0M | $-154.0K | ||
| Q1 25 | $-6.1M | $23.5M | ||
| Q4 24 | $-10.3M | $18.9M | ||
| Q3 24 | $-10.4M | $5.7M | ||
| Q2 24 | $-796.0K | $-6.5M | ||
| Q1 24 | $-3.7M | $13.8M |
| Q4 25 | -125.6% | — | ||
| Q3 25 | -47.7% | — | ||
| Q2 25 | -30.3% | -6.9% | ||
| Q1 25 | -19.0% | 44.4% | ||
| Q4 24 | -128.8% | 46.4% | ||
| Q3 24 | -36.9% | 12.3% | ||
| Q2 24 | -1.6% | -33.7% | ||
| Q1 24 | -10.7% | 28.1% |
| Q4 25 | -125.8% | — | ||
| Q3 25 | -47.5% | — | ||
| Q2 25 | -30.3% | -0.8% | ||
| Q1 25 | -18.9% | 46.2% | ||
| Q4 24 | -129.8% | 49.6% | ||
| Q3 24 | -36.3% | 17.2% | ||
| Q2 24 | -2.3% | -26.0% | ||
| Q1 24 | -11.0% | 33.3% |
| Q4 25 | $-3.89 | — | ||
| Q3 25 | $-23.52 | — | ||
| Q2 25 | $-18.94 | — | ||
| Q1 25 | $-20.73 | — | ||
| Q4 24 | $97.71 | — | ||
| Q3 24 | $-305.04 | — | ||
| Q2 24 | $-98.64 | — | ||
| Q1 24 | $-125.46 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.4M | $49.0M |
| Total DebtLower is stronger | $509.8M | — |
| Stockholders' EquityBook value | $265.4M | $119.9M |
| Total Assets | $859.2M | $175.1M |
| Debt / EquityLower = less leverage | 1.92× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.4M | — | ||
| Q3 25 | $17.3M | — | ||
| Q2 25 | $27.8M | $49.0M | ||
| Q1 25 | $19.8M | $47.6M | ||
| Q4 24 | $20.3M | $38.1M | ||
| Q3 24 | $18.5M | $40.6M | ||
| Q2 24 | $29.3M | $43.2M | ||
| Q1 24 | $21.3M | $36.2M |
| Q4 25 | $509.8M | — | ||
| Q3 25 | $527.8M | — | ||
| Q2 25 | $535.6M | — | ||
| Q1 25 | $512.7M | — | ||
| Q4 24 | $505.7M | — | ||
| Q3 24 | $478.3M | — | ||
| Q2 24 | $485.1M | — | ||
| Q1 24 | $472.8M | — |
| Q4 25 | $265.4M | — | ||
| Q3 25 | $281.9M | — | ||
| Q2 25 | $287.1M | $119.9M | ||
| Q1 25 | $293.0M | $25.0M | ||
| Q4 24 | $304.5M | $-456.0K | ||
| Q3 24 | $321.0M | $-23.5M | ||
| Q2 24 | $351.1M | $-31.2M | ||
| Q1 24 | $369.9M | $-31.7M |
| Q4 25 | $859.2M | — | ||
| Q3 25 | $871.8M | — | ||
| Q2 25 | $885.0M | $175.1M | ||
| Q1 25 | $882.3M | $98.5M | ||
| Q4 24 | $889.6M | $120.5M | ||
| Q3 24 | $868.0M | $139.0M | ||
| Q2 24 | $891.2M | $159.2M | ||
| Q1 24 | $887.5M | $184.7M |
| Q4 25 | 1.92× | — | ||
| Q3 25 | 1.87× | — | ||
| Q2 25 | 1.87× | — | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 1.66× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.38× | — | ||
| Q1 24 | 1.28× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.8M | $-15.8M |
| Free Cash FlowOCF − Capex | — | $-15.8M |
| FCF MarginFCF / Revenue | — | -84.6% |
| Capex IntensityCapex / Revenue | — | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.8M | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $-2.5M | $-15.8M | ||
| Q1 25 | $1.2M | $-21.0M | ||
| Q4 24 | $17.0M | $-19.9M | ||
| Q3 24 | $10.3M | $-20.7M | ||
| Q2 24 | $3.9M | $-19.5M | ||
| Q1 24 | $1.6M | $-26.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-15.8M | ||
| Q1 25 | — | $-21.2M | ||
| Q4 24 | — | $-20.0M | ||
| Q3 24 | — | $-20.7M | ||
| Q2 24 | — | $-19.6M | ||
| Q1 24 | — | $-26.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -84.6% | ||
| Q1 25 | — | -41.6% | ||
| Q4 24 | — | -52.5% | ||
| Q3 24 | — | -62.1% | ||
| Q2 24 | — | -78.2% | ||
| Q1 24 | — | -63.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 0.3% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | — | -1.05× | ||
| Q3 24 | — | -3.61× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMCT
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
